Becton, Dickinson, and Company announced the results of a peer-reviewed study. The peer-reviewed study was conducted to reduce hazardous drug surface contamination.
Merck KGaA signed a non-binding Memorandum of Understanding (MoU) with Synplogen. Both companies are noticed to focus on manufacturing and testing for viral vector gene therapies for Japan.
Author Credits: Radhika Gupta, Shivam Bhutani